Compare Agnico Eagle Mines Ltd (AEM) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Biogen Inc — how do they compare? Agnico Eagle Mines Ltd trades at $185.25 (market cap $92.01B), while Biogen Inc trades at $206.47 (market cap $30.13B). The key difference: Agnico Eagle Mines Ltd is far larger — about 3.1× Biogen Inc's market cap, and Agnico Eagle Mines Ltd pays a 0.99% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| AEM | BIIB | |
|---|---|---|
Market Cap | $92.01B | $30.13B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $216.63 |
52-Week Low | $130.23 | $128.93 |
Enterprise Value | $88.85B | $37.20B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $185.82, up 2.96% on the day, reflecting strong momentum amid record gold prices and robust earnings. The stock exhibits a bullish technical setup with support near $180 and resistance at $186, while fundamentals are supported by a 37.5% net income margin and consistent earnings beats. Recent news highlights operational strength, with Q2 2026 EPS of $3.05 surpassing estimates and management projecting 20-30% production growth organically.
Outlook remains positive given analyst consensus and gold's uptrend, but rising unit costs and production challenges pose risks. With a $219.63 average price target implying 18% upside, AEM offers growth exposure to gold, though investors should monitor cost inflation and execution of expansion plans.
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
